ARCHIVES

Phase III Trial: Panobinostat Increases PFS by Four Months

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

President’s Budget Would Permit NCI Funding Of Only 23.2% Of Approved Traditional Grants

January 26, 1979

FDA Invites Ad Hoc Consumer Reps To ODAC Meetings

February 17, 1995

Cancer Letter Accepts “Substantial” Settlement In New Copyright Claim

August 5, 1988

Needed Enhancement Or Unfunded Mandate? New NCI Program To Merge CCOP, NCCCP

July 13, 2012

In Brief: Sartorelli Replaces Cole As Director Of Yale Comprehensive Center; NSABP Ends Segmental Trials

March 2, 1984

Amgen Announces Cochrane Findings: ESAs Increase Risk Of On-Study Death.

October 3, 2008